The US FDA has approved etripamil, a calcium channel blocker nasal spray indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. Clinical evidence In a clinical study involving 692 patients, 59.6% converted to normal sinus rhythm within 30 minutes, with a median conversion time of 18.5 minutes, demonstrating its effectiveness in achieving rapid rhythm control during PSVT episodes. Dosage and administration Available as a nasal spray Initial dosage: A dose of 70 mg is administered as two nasal sprays, one spray into each nostril.
Each nasal spray device delivers two sprays. The two sprays together contain a total of 70 mg etripamil. Repeat dosage (if needed): Should symptoms persist for 10 minutes after administration of etripamil, take a second dose of 70 mg administered as two nasal sprays, one spray into each…
